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ABSTRACT
We investigated the effect of the long-actingmuscarinic antagonist aclidiniumbromide on chronic obstruc-
tive pulmonary disease (COPD) exacerbations by pooling data from five randomized, placebo-controlled,
parallel-group Phase III studies of 3–6 months’ duration. Data were pooled from the aclidinium 400 μg
twice-daily (BID) and placebo arms (N = 2,521) and stratified by Global initiative for chronic Obstructive
LungDisease (GOLD) group (A, B, C andD). Results showed that fewer patients experienced1 exacerbation
with aclidinium (any severity: 12.5%;moderate to severe: 10.9%) comparedwith placebo (any severity: 15.7%;
moderate to severe: 13.3%) and the odds of experiencing 1 exacerbation of any severity were reduced in
patients receiving aclidinium (odds ratio = 0.78, p = 0.039). Furthermore, aclidinium reduced the rate
of exacerbations compared with placebo (any severity: rate ratio = 0.79, p = 0.026; moderate to severe:
0.80, p = 0.044). The time to first exacerbation of any severity was delayed with aclidinium compared with
placebo (hazard ratio = 0.79,p = 0.026) and therewas a numerical delay in time to firstmoderate-to-severe
exacerbation. Finally, the effects of aclidinium on exacerbations versus placebo were greater in patients in
GOLD Groups B and D; however, it is of note that only 10.7% of patients were classified in Group A or C.
In summary, the results indicate that aclidinium 400 μg BID reduces the frequency of COPD exacerbations
compared with placebo and that these effects are greater in symptomatic patients.
Introduction
Exacerbations in patients with chronic obstructive pulmonary
disease (COPD) are associated with an accelerated decline of
lung function (1–4), impaired health status (5–7) and increased
mortality (8). Exacerbations of COPD, particularly those requir-
ing hospitalizations, are a major contributor to the economic
burden of COPD (9,10). The prevention of COPD exacerbations
is an important longer-term goal of COPD therapy (11).
Recent studies have provided evidence that long-acting mus-
carinic antagonists (LAMAs) can reduce the frequency of exac-
erbations versus placebo (12,13) or—in a population enriched
for exacerbations—versus long-acting β2-agonists (LABAs)
(14,15). Indeed, the 2014 Global initiative for chronic Obstruc-
tive Lung Disease (GOLD) guidelines recommended LAMAs as
maintenance therapy for patients with a high risk of exacerba-
tion (2 exacerbations or 1 exacerbation leading to hospital-
ization in the previous year, or severe airflow limitation [GOLD
Stage III and IV]) and/or a high level of symptoms (GOLD
Groups B, C and D) (11).
Aclidinium bromide 400 μg is a twice-daily (BID) LAMA
indicated as amaintenance therapy for patientswithCOPD (16).
Although exacerbations have been assessed in Phase III clini-
cal studies of aclidinium and its combination with formoterol
(5,17–22), the individual studies were not designed to assess
CONTACT Jadwiga A. Wedzicha w.wedzicha@imperial.ac.uk Airways Disease Section, National Heart and Lung Institute, Imperial College London, Guy Scadding
Building, Dovehouse Street, London SW LY, United Kingdom.
exacerbations as a primary endpoint. Here, we investigated the
effect of aclidiniummonotherapy on exacerbations using pooled
data from five Phase III studies of 3–6 months’ duration. Addi-
tionally, we performed a novel exploratory analysis to assess the
differential effect of aclidinium on exacerbations according to
the GOLD Groups (A, B, C and D).
Methods
Study design
Data were pooled from the aclidinium 400 μg BID monother-
apy and placebo arms of five studies in patients with moderate-
to-severe COPD, of which three studies were designed to assess
the efficacy and safety of aclidinium monotherapy (ACCORD
I [NCT00891462], ACCORD II [NCT01045161] and ATTAIN
[NCT01001494]), and two were designed to assess the efficacy
and safety of aclidinium/formoterol combined (ACLIFORM
[NCT01462942] and AUGMENT [NCT01437397]; Table 1).
All five studies were multinational, multicenter, randomized,
double-blind and parallel-group in design. Detailed methods of
each study have been published elsewhere (5,17–20,22). Acli-
dinium 400 μg and placebo were administered in the morning
and evening via a breath-actuatedmultidose dry powder inhaler
(GenuairTM/Pressair®1).
Article © Jadwiga A. Wedzicha, Alvar Agusti, Gavin Donaldson, Ferran Chuecos, Rosa Lamarca, and Esther Garcia Gil. This is an Open Access article. Non-commercial re-use, distribution, and
reproduction in any medium, provided the original work is properly attributed, cited, and is not altered, transformed, or built upon in any way, is permitted. The moral rights of the named authors
have been asserted.
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2 J. A. WEDZICHA ET AL.
Table . Study designs.
Study name
ClinicalTrials.gov
registration
Treatment
weeks Treatment arms
Randomized
patients
Monotherapy
ACCORD I NCT  Aclidinium μg
BID, Aclidinium
μg BID,
Placebo

ACCORD II NCT  Aclidinium μg
BID, Aclidinium
μg BID,
Placebo

ATTAIN NCT  Aclidinium μg
BID, Aclidinium
μg BID,
Placebo

Combination therapy
ACLIFORM NCT  Aclidinium/
formoterol
/μg BID,
Aclidinium/
formoterol
/μg BID,
Aclidinium μg
BID, Formoterol
μg BID, Placebo
,
AUGMENT NCT  Aclidinium/
formoterol
/μg BID,
Aclidinium/
formoterol
/μg BID,
Aclidinium μg
BID, Formoterol
μg BID, Placebo
,
BID, twice-daily.
Patients
Male and female patients aged 40 years who were current
or former smokers (10 pack-years) with moderate-to-severe
COPD (post-bronchodilator forced expiratory volume in 1 sec-
ond [FEV1] 30% and <80% predicted and FEV1/FVC ratio
<70%) were eligible for inclusion in the studies. A history of1
exacerbation was not an inclusion criterion. Exclusion criteria
included presence or history of clinically significant respiratory
disease (other than COPD) or cardiovascular conditions, respi-
ratory infection or COPD exacerbation6 weeks pre-screening
and hospitalization for COPD exacerbation 3 months
pre-screening.
Inhaled salbutamol (100 μg/puff) was permitted as relief
medication, provided its use was discontinued 6 hours prior to
study visits. Inhaled corticosteroids (ICS), oral or parenteral cor-
ticosteroids (equivalent to10 mg/day of prednisone or 20 mg
every other day), oral sustained-release methylxanthines and
oxygen therapy (<15 hours/day) were allowed, provided treat-
ment was stable 4 weeks pre-screening. Other long-acting
bronchodilators were prohibited.
Study protocols were approved by all necessary ethics com-
mittees. All patients provided written informed consent.
Assessment of exacerbations
COPD exacerbations were assessed by the investigator using
the Healthcare Resource Utilization definition (an increase of
COPD symptoms during 2 consecutive days that required a
change in COPD treatment). Exacerbations were categorized
as mild (self-managed by the patient at home by increasing
usual COPD medication [short-acting bronchodilator and/or
ICS use]), moderate (did not lead to hospitalization, but were
treated with antibiotics and/or systemic corticosteroids or an
increase in dose of systemic corticosteroids) or severe (led to
hospitalization [overnight stay or emergency room visit]). A
COPD exacerbation was considered a new exacerbation episode
if the patient had not taken oral steroids and antibiotics for
14 days since the previous exacerbation.
Statistical analysis
Individual data were pooled from the aclidinium
monotherapy and placebo arms of the intent-to-treat (ITT) pop-
ulation (all patients who received at least one dose of the study
medication and had a baseline and at least one post-baseline
FEV1 assessment) in each study. Exacerbation rates were annu-
alized by dividing the number of exacerbations by the number
of days the patient participated and multiplying by 365.25.
For analyses of exacerbation rates and time to first exac-
erbation, data were stratified according to the GOLD COPD
assessment (Groups A, B, C and D) based on level of symptoms
(St. George’s Respiratory Questionnaire [SGRQ] total score<25
[Groups A and C] or25 [Groups B and D] (23)), airflow lim-
itation severity (GOLD Stage I or II vs. III or IV) and previous
exacerbation history (1 vs.2 within the previous year) (24).
For further analysis, patients were also pooled by level of symp-
toms (low [GroupA+C] vs. high [Group B+D]). Data were also
stratified by baseline ICS use for analyses of exacerbation rates.
Whether or not patients experienced1COPDexacerbation
was analyzed based on a logistic regression model with treat-
ment group, study, smoking status and baseline airflow limi-
tation severity as factors. The number of COPD exacerbations
was analyzed using a negative binomial regression model with
the total number of COPD exacerbations as response. Expo-
sure time was included as an offset. Time to first exacerbation
was analyzed using a Cox proportional hazard model, with time
from first study dose to failure (an exacerbation) right censored
by study termination (withdrawal or study end – whichever
occurred first). Both models included age, treatment group,
study, sex, baseline ICS use, baseline airflow limitation severity
and smoking status as covariates.
Results
Patients
In total, 2,521 patients were included in the pooled analysis
(ITT population). Patient demographics and baseline charac-
teristics were similar across the five studies, although ATTAIN
and ACLIFORM had a higher proportion of male patients and
AUGMENT had fewer patients with 1 exacerbation in the
12 months prior to study entry (Table 2). Overall, 28.3% of
patients had experienced 1 exacerbation in the previous year
(Table 2). The majority of patients were classified in GOLD
Groups B (41.4%) and D (47.9%; Figure 1). Most patients in
GOLDGroupDwere classified as such due to a FEV1 lower than
50% of the reference. ICS use was similar between treatment
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Table . Patient demographics and baseline characteristics (ITT population).
ACCORD I ACCORD II ATTAIN ACLIFORM AUGMENT
Pooled placebo
arms
Pooled
aclidinium
μg BID
arms Overall
Number of patients a a a a a , , ,a
Age, years, mean (SD) . (.) . (.) . (.) . (.) . (.) . (.) . (.) . (.)
Male (%) . . . . . . . .
Current smoker (%) . . . . . . . .
Smoking history,
pack-years, mean (SD)
. (.) . (.) . (.) . (.) . (.) . (.) . (.) . (.)
Post-bronchodilator FEV
(% predicted)
. (.) . (.) . (.) . (.) . (.) . (.) . (.) . (.)
COPD severity (GOLD stage) (%)
Stage I (mild) . . . . . . . .
Stage II (moderate) . . . . . . . .
Stage III (severe) . . . . . . . .
Stage IV (very severe) . . . . . . . .
Patients with
exacerbation prior to
study entry (%)
. . . . . . . .
Patients with SGRQ total
score (%)
. . . . . . . .
aIncludes patients in the aclidinium μg and placebo arms.
BID, twice-daily; COPD, chronic obstructive pulmonary disease; FEV, forced expiratory volume in  second; GOLD, Global initiative for chronic Obstructive Lung Disease;
ITT, intent-to-treat; SD, standard deviation; SGRQ, St. George’s Respiratory Questionnaire.
groups in each study. Overall, 39.5% of patients in the placebo
group and 38.3% of patients in the aclidinium group were using
concomitant ICS (Figure 2).
Number of exacerbations
In the pooled analysis, 12.5% of patients in the aclidinium
group and 15.7% of patients in the placebo group had 1
exacerbation of any severity; the odds of a patient experiencing
1 exacerbation of any severity were reduced with aclidinium
400 μg versus placebo (odds ratio [OR] = 0.78, p = 0.039;
Table 3). In addition, in four of the five individual studies, the
proportion of patients who experienced 1 COPD exacerba-
tion of any severity was greater in the placebo group than in
Figure . Pooled analysis population, stratiﬁed by GOLD group (ITT population).
aPatients had FEV –% predicted. There were  patients with insuﬃcient
data for GOLD classiﬁcation. ITT, intent-to-treat; GOLD, Global initiative for chronic
Obstructive Lung Disease; N, number of patients in aclidinium μg and placebo
groups.
the aclidinium group (Table 3). Similarly, the proportion of
patients who experienced 1 moderate-to-severe exacerbation
was numerically lower with aclidinium compared with placebo
in each study; however, these results did not reach statistical
significance at the study level or overall (Table 3).
Rate of exacerbations
In the pooled data, aclidinium reduced the rate of exacerbations
of any severity compared with placebo (rate ratio [RR] = 0.79,
p = 0.026; Figure 3A). By GOLD group, the reduction in the
rate of exacerbations with aclidinium compared with placebo
was greatest in GOLD Groups B and D (Figure 3B) and a rate
reduction was also observed with aclidinium in GOLD Group
D and GOLD Group B+D (Group D: RR = 0.76, p = 0.052;
Group B+D: RR = 0.78, p = 0.025; Figure 3B). Results for
Groups A and C are not shown individually due to the low num-
ber of patients and non-convergence of the statistical model.
Additionally, the rate of exacerbations of any severity was very
low in Groups A and C (placebo: 0.20 and 0.05 exacerbations
per patient per year, respectively) compared with Groups B and
D (placebo: 0.44 and 0.74 exacerbations per patient per year,
respectively).
The data for moderate-to-severe exacerbations followed a
similar pattern to the data for exacerbations of any severity, with
a reduction in exacerbation rate with aclidinium compared with
placebo (RR = 0.80, p = 0.044; Figure 4A). Figure 4B presents
data for the rate of moderate-to-severe exacerbations stratified
by GOLD group. The reduction in rate of moderate-to-severe
exacerbations with aclidinium versus placebo was greatest in
GOLD Group D (RR = 0.73, p = 0.045) and there was a
reduction in GOLD Group B+D (RR = 0.78, p = 0.031).
Again, the data for Groups A and C are not presented individu-
ally for the reasons stated above. The rate of moderate-to-severe
exacerbations in Groups B and D was higher than in Groups A
and C (placebo rates: 0.38 and 0.63 exacerbations per patient
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4 J. A. WEDZICHA ET AL.
Figure . Concomitant ICS use by study and overall (ITT population). ICS, inhaled corticosteroid; ITT, intent-to-treat;N, number of patients in aclidiniumμg and placebo
groups.
per year vs. 0.10 and 0.01 exacerbations per patient per year,
respectively).
When stratified by concomitant ICS use, exacerbation
rates were numerically higher in patients who were using
ICS compared with those who were not using ICS (Table 4).
In addition, there was a reduction in exacerbation rate with
aclidinium 400 μg versus placebo for exacerbations of any
severity (p < 0.026) and moderate-to-severe exacerbations
in the overall patient group (p < 0.044), but not those with
concomitant ICS use or those without concomitant ICS use
when considered separately (Table 4).
Time to first exacerbation
Aclidinium increased the time to first exacerbation of any sever-
ity compared with placebo overall (hazard ratio [HR] = 0.79,
p = 0.026; Figure 5A) and for patients in GOLD Group B+D
(HR = 0.79, p = 0.031; Figure 5C) but not GOLDGroup A+C
(HR = 0.99, p = 0.972; Figure 5B). The changes in time
to first moderate-to-severe exacerbation with aclidinium versus
placebo followed a similar pattern (all patients: HR = 0.82, p =
0.081; Group B+D:HR = 0.81, p = 0.073; GroupA+C:HR =
1.37, p = 0.511).
Discussion
This pooled analysis shows that aclidinium 400 μg BID reduces
the frequency of exacerbations in patients with COPD with
moderate-to-severe airflow limitation. Specifically, the number
of exacerbations of any severity was reduced with aclidinium
compared with placebo (p = 0.039), as was the annual rate of
both moderate-to-severe exacerbations (p = 0.044) and exac-
erbations of any severity (p = 0.026). Additionally, aclidinium
400 μg delayed the time to first exacerbation of any severity
in all patients (p = 0.026); however, the delay in the time to
first moderate-to-severe exacerbation did not reach statistical
Table . Patients with exacerbation.
Monotherapy Combination therapy
-month studies -month studies
ACCORD I ACCORD II ATTAIN ACLIFORM AUGMENT Overall
Number of patients    a a ,a
Patients with exacerbation of any severity, %
Aclidinium μg . . . . . .
Placebo . . . . . .
OR vs. placebo . . . . . .
p-value . . . . . .
Patients with moderate-to-severe exacerbation, %
Aclidinium μg . . . . . .
Placebo . . . . . .
OR vs. placebo . . . . . .
p-value . . . . . .
aExacerbations analyses from the individual ACLIFORM and AUGMENT studies are reported for the ITT-exacerbations populations ( and  patients, respectively; all
patients who received at least one dose of the studymedication), as speciﬁed in the study protocols and published previously (,); pooled analyses include data from
the ITT populations ( and  patients, respectively; all patients who received at least one dose of the study medication and had a baseline and post-baseline
FEV assessment) for consistency with the ACCORD I, ACCORD II and ATTAIN study populations.
ITT, intent-to-treat; OR, odds ratio
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COPD: JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 5
Figure . Rate of COPD exacerbations of any severity (A) overall (individual studies and pooled analyses)a and (B) stratiﬁed byGOLDgroup (pooled analysis). aExacerbations
analyses from the individual ACLIFORM and AUGMENT studies are reported for the ITT-exacerbations populations of the aclidinium monotherapy and placebo arms only
( and  patients, respectively; all patients who received at least one dose of the studymedication), as speciﬁed in the study protocols and published previously (,);
pooled analyses include data from the ITT populations ( and  patients, respectively; all patients who received at least one dose of the study medication and had a
baseline and post-baseline FEV assessment) for consistency with the ACCORD I, ACCORD II and ATTAIN study populations. Percentages are the proportion of all GOLD-
classiﬁed patients (N = ,) in each GOLD group. CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive
Lung Disease; ITT, intent-to-treat; RR, rate ratio; N, number of patients in aclidinium μg and placebo groups.
significance. Finally, the reduction in exacerbation frequency
was most apparent in GOLD Groups B and D (i.e. patients with
more symptoms), although it should be noted that patient num-
bers inGroupsA andCwere low (10.7% of the total population).
In this pooled analysis, aclidinium 400 μg reduced the
rate of exacerbations of any severity and moderate-to-severe
exacerbations by approximately 20% compared with placebo.
These results are consistent with recent studies of other
LAMAs. For example, the 26-week GLOW 1 study and the
52-week GLOW 2 study demonstrated reduced rates of exac-
erbations of 28–34% with glycopyrrolate 50 μg once daily
(QD) versus placebo (13). The 4-year UPLIFT trial showed
a 14% reduction in rate of exacerbations with tiotropium
18 μg QD versus placebo (although it should be noted
that LABAs and ICS were allowed as concomitant medica-
tion) (12), in contrast to most short-term studies. Similar
to the GLOW and UPLIFT studies, our study populations
were not enriched for exacerbations, and although reductions
in the rate of exacerbations were observed with aclidinium ver-
sus placebo, treatment effects may be greater in a population
with a history of exacerbations. Indeed, the highest rates of
exacerbation were observed in symptomatic patients (GOLD
Groups B and D) and it was these patients who displayed the
largest reductions in exacerbation rates with aclidinium versus
placebo. The 1-year MISTRAL study included a patient popu-
lation enriched for exacerbations and found a 35% reduction in
rate of exacerbations with tiotropium 18 μg QD versus placebo
(25). Greater reductions in exacerbation rates have also been
demonstrated with LAMAs compared with LABAs in patient
populations enriched for exacerbations (14,15). Similarly, in the
present analysis, aclidinium significantly reduced exacerbations
of any severity in patients with concomitant ICS use but not
patients without concomitant ICS use, and this may be due to
the higher exacerbation rate in patients who are prescribed ICS.
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Figure . Rate of moderate-to-severe COPD exacerbations (A) overall (individual studies and pooled analyses)a and (B) stratiﬁed by GOLD group (pooled analysis).
aExacerbations analyses from the individual ACLIFORM and AUGMENT studies are reported for the ITT-exacerbations populations of the aclidinium monotherapy and
placebo arms only ( and  patients, respectively; all patients who received at least one dose of the study medication), as speciﬁed in the study protocols and pub-
lished previously (,); pooled analyses include data from the ITT populations ( and  patients, respectively; all patients who received at least one dose of the
studymedication and had a baseline and post-baseline FEV assessment) for consistency with the ACCORD I, ACCORD II and ATTAIN study populations. Percentages are
the proportion of all GOLD-classiﬁed patients (N = ,) in each GOLD group. CI, conﬁdence interval; GOLD, Global initiative for chronic Obstructive Lung Disease; ITT,
intent-to-treat; RR, rate ratio; N, number of patients in aclidinium μg and placebo groups.
In addition to the effects on exacerbation rates, we observed a
delay in time to first exacerbation of any severitywith aclidinium
versus placebo and a delay in time to first moderate-to-severe
exacerbation. Again, these results are consistent with previous
studies with other LAMAs (12,13); however, it should be noted
that comparing the treatment effects in our pooled analysis with
those observed in other studies can be problematic due to major
differences in study design (e.g. differences in patient popula-
tion, treatment duration, allowed concomitant medications and
exacerbation endpoints).
Investigating the effects of treatment on exacerbations
according to the new GOLD classification may be useful for
identifying differences in response in different GOLD groups
and thus predicting which patients will respond better to a
particular therapy. However, our sub-group analysis is lim-
ited by the low patient numbers and rate of exacerbations
in GOLD Groups A and C. The distribution of patients
across GOLD groups will depend on the methods used for
GOLD classification (i.e. modified Medical Research Council
vs. COPD Assessment Test vs. SGRQ and airflow limitation vs.
exacerbation history vs. both) (26–29). The COPDgene study
used the same classification parameters (SGRQ, airflow lim-
itation and exacerbation history) as our pooled analysis and
reported a higher proportion of patients in Group A (29.4% vs.
8.1%), a lower proportion in Group B (24.7% vs. 47.9%) and a
similar proportion in Groups C (4.9% vs. 2.6%) and D (41.0%
vs. 41.4%) (23). These results suggest that a greater proportion
of patients had an SGRQ score25 in our pooled analysis com-
pared with the COPDgene study, possibly a consequence of dif-
ferent inclusion criteria (patients with moderate-to-severe vs.
any severity of airflow limitation) or geographical variations in
SGRQ due to real or perceived differences in health status (our
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Table . Exacerbation rates stratiﬁed by concomitant ICS use (ITT population).
Overall ICS No ICS
Rate of exacerbations of any severity (per patient per year)
Aclidinium μg,
N = ,
. . .
Placebo, N = , . . .
RR vs. placebo . . .
p-value . . .
Rate of moderate-to-severe exacerbations (per patient per year)
Aclidinium μg,
N = ,
. . .
Placebo, N = , . . .
RR vs. placebo . . .
p-value . . .
ICS, inhaled corticosteroid; ITT, intent-to-treat; N, number of patients; RR, rate ratio.
Figure . Time to ﬁrst COPD exacerbation of any severity in (A) all patients; (B)
patients in GOLD Groups A and C; and (C) patients in GOLD Groups B and D (ITT
population). COPD, chronic obstructive pulmonary disease; GOLD, Global initiative
for chronic Obstructive Lung Disease; HR, hazard ratio; ITT, intent-to-treat; N, num-
ber of patients.
pooled analysis included study sites in North America, Europe,
Africa and the Asia-Pacific region; the COPDgene study was
conducted in North America) (23).
The mechanisms by which LAMAs may help prevent COPD
exacerbations are not well understood (30). Various mecha-
nisms have been proposed, including improved lung mechanics
and bronchodilation, reduced lung hyperinflation, reduced air-
way resistance, improved inspiratory capacity, reduced sputum
production, inhibition of viral activity in the lung, and direct and
indirect effects on lung inflammation (30).
Pooling of data from studies with similar designs can confirm
trends that are observed/reveal trends thatmay not be evident in
the individual studies, particularly when the event rate is low. In
this analysis, pooling of data gave a sufficient number of patients
in each GOLD group for exploratory sub-group analyses.
One potential limitation of this pooled analysis is the rel-
atively short duration of the five studies. However, a recent
systematic review of tiotropium versus placebo showed sim-
ilar reductions in exacerbation rates in studies of <1 year
(13 studies of 3–6 months and one study of 9 months) and
studies of 1 year (six studies of 1 year, one study of 2 years
and one study of 4 years) (31), suggesting that shorter studies
can still provide reliable estimates of treatment effect. Another
potential limitation is the use of SGRQ for segregating GOLD
classification groups as GOLD only uses the modified Medical
Research Council dyspnoea scale, COPD assessment test or
Clinical COPD Questionnaire for this purpose (11).
Conclusions
The results of this pooled analysis add to the growing body
of evidence that the use of a LAMA as maintenance therapy
can help prevent exacerbations of COPD by demonstrating an
effect within a relatively short period of time (3–6 months).
In a population of patients with COPD that is not enriched
for exacerbations, aclidinium 400 μg BID may reduce the
frequency of exacerbations by approximately 20% compared
with placebo. The treatment effect may have been greater in
symptomatic patients because these patients had higher rates
of exacerbation compared with non-symptomatic patients and
reductions in rate are more likely to be observed in patients
with more frequent exacerbations.
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